Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
NCT02862275Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in hematopoietic and lymphoid cell neoplasm and malignant solid neoplasm, sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events at 6 weeks. Started May 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
hematopoietic and lymphoid cell neoplasmmalignant solid neoplasm
Beyond the preview
Go deeper on NCT02862275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862275.